The patent covers the method of using intranasal administration of Ampligen with a seasonal influenza vaccine to boost immune response against a H5N1 avian influenza infection compared to the administration of seasonal influenza vaccine alone.
The aim of the approach reported in new patent of Hemispherx is to generate protective mucosal immunity against newly emerging and pathogenic forms of H5N1 avian influenza viruses.